Loading...
Please wait, while we are loading the content...
Lenalidomide in follicular lymphoma
| Content Provider | Scilit |
|---|---|
| Author | Flowers, Christopher R. Leonard, John P. Fowler, Nathan H. |
| Copyright Year | 2020 |
| Description | Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single-agent rituximab and may become an alternative to chemoimmunotherapy. |
| Related Links | https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2019001751/1723054/blood.2019001751.pdf |
| Ending Page | 2136 |
| Page Count | 4 |
| Starting Page | 2133 |
| DOI | 10.1182/blood.2019001751 |
| Journal | Blood |
| Issue Number | 24 |
| Volume Number | 135 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2020-06-11 |
| Access Restriction | Open |
| Subject Keyword | Hematology Safety Treatment Efficacy Chemotherapy Follicular Lymphoma Rituximab Lenalidomide Chemoimmunotherapy Journal: Blood (Vol- 2006, Issue- 24) |
| Content Type | Text |
| Resource Type | Article |